Skip to content
Hims & Hers 2025 Recap + 2026 Predictions episode artwork

Jan 21, 2026 56 min

Hims & Hers 2025 Recap + 2026 Predictions

from Hims House Hosted by Jonathan Stern

In episode 51 of Hims House, Bayside returns to the podcast to for year-end recap + 2026 predictions. The conversation covers Hims & Hers’ eventful 2025—international expansion, acquisitions, new product categories, partnerships and breakups—before pivoting to what investors should watch for in 2026. Bayside, who shifted to a more cautious stance mid-2025, explains his current thinking on valuation, growth rates, and the catalysts that could change the narrative. The episode closes with bold predictions about tirzepatide, a potential Super Bowl ad, and where the stock might trade heading into earnings. 00:00 - Welcome back to Bayside 01:10 - 2025 Recap: Labs, testosterone, menopause, international, acquisitions (Livewell, YourBio), $250M buyback, Deb Autor as Chief Policy Officer 03:21 - Revenue concerns 08:45 - Valuation framework 11:30 - Is compounding still at risk? 16:51 - The competitive landscape 20:22 - Super Bowl Ad Speculation 24:15 - Tirzepatide?! 29:32 - Peptides Opportunity 32:13 - Novo partnership “active talks” 38:13 - 2026 predictions 45:30 - Wearables? 50:10 - Celebrity partnership gap Get full access to Hims House at himshouse.substack.com/subscribe

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

Hims & Hers 2025 Recap + 2026 Predictions

0:00 56:51

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of Hims House?

This episode is 56 minutes long.

When was this Hims House episode published?

This episode was published on January 21, 2026.

Can I download this Hims House episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.